article
Drug Target Review – Issue 3 2023
A new Drug Target Review issue is now ready to download! This issue features articles on vaccine development, artificial intelligence and organoids.
List view / Grid view
Informatics
webinar
Turning Plans into Reality: Real Examples of Custom Automation Projects
24 August 2023 | By Bio-Rad Laboratories Inc.
Watch our industry experts to learn about the tangible benefits and best practice of custom flow cytometry automation projects. You’ll discover how to reduce your challenges implementing tailored automation, controlling the quality of the data produced and improving the reliability of your data acquisition.
news
Artificial intelligence cell analysis for swift blood disease diagnosis
Researchers from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an artificial intelligence (AI) system capable of identifying and characterising white and red blood cells within microscopic images of blood samples. This AI algorithm holds the potential to aid medical professionals in diagnosing blood…
news
New computational tool may fuel vaccine development
La Jolla biologists harness machine learning and computational tools to make sense of immune system data.
podcasts
Episode 20- Regulations on artificial intelligence- impact on drug discovery
Tune in to this episode to hear experts discussing the hot topic that is AI and how AI technology is used in drug discovery, looking specifically at how Biotechs & Pharma are trying to keep up with emerging technology.
news
Harnessing machine learning for early cancer detection in primary care
Machine learning (ML) presents a promising opportunity to revolutionize early cancer detection in primary care, addressing the challenges associated with diagnostic errors and improving patient outcomes. The potential of ML in this field is highlighted in a recent paper published in Oncoscience
article
Navigating the challenges and opportunities of AI in drug development and personalised medicine
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
article
Unleashing the power of AI in target discovery and resilience against disease
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting…
article
Drug Target Review – Issue 2 2023
A new Drug Target Review issue is now ready to download! This issue features articles on cell and gene therapy, imaging and screening.
video
Video: Four integrated technologies for biologics developability assessment
The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics.
news
New class of ribosomal peptide “daptides” discovered by researchers
Researchers from the University of Illinois have identified a new class of ribosomally synthesised and post-translationally modified peptides (RiPPs) named "daptides" that have haemolytic activity.
article
The future of lab automation: streamlining drug research
In this article, Drug Target Review's Ria Kakkad and Izzy Wood explore the results of the latest research on lab automation techniques and technologies designed to accelerate drug discovery.
article
Drug Target Review – Issue 1 2023
A new Drug Target Review is now ready to download! This issue features articles which explore antibodies, vaccines and assays.
podcasts
Episode 18 – Scaling up organoids
Tune into this podcast to hear experts discussing scaling up 3D organoids!
news
AI tools aid the discovery of super tight-binding antibodies
An AI strategy developed by US scientists could accelerate the development of new antibody drugs.
